IDEXX Labs posts 9% organic growth, raises EPS forecast, driven by global diagnostic expansion.

IDEXX Laboratories reported 9% organic revenue growth in Q2 2026 and raised its EPS guidance to $14.69–14.94, reflecting strong demand for its veterinary diagnostic products. While growth in its core US market is slowing, international expansion remains in early stages, offering long-term growth potential. Despite a premium valuation, improved free cash flow and capital allocation support a positive outlook for investors. The company’s focus on companion animal diagnostics underpins its durable competitive advantage and recurring revenue model.